Evidence map›Paper›PMID 40514404›Full record

ArticleNPJ Parkinson's disease2025

Elevated cerebrospinal fluid levels of SERPIN E1 in participants with lewy body diseases.

Milan Zimmermann, Madeleine Fandrich, Meike Jakobi, Benjamin Röben, Isabel Wurster, Stefanie Lerche, Claudia Schulte, Shahrzad Zimmermann, Christian Deuschle, Nicole Schneiderhan-Marra and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ Parkinson's disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Milan ZimmermannDepartment of Neurodegeneration and Hertie-Institute for Clinical Brain Research, Center of Neurology, University of Tuebingen, Tuebingen, Germany. milan.zimmermann@uni-tuebingen.de.ORCID http://orcid.org/0000-0001-7066-7749
Madeleine FandrichNMI Natural and Medical Sciences Institute at the University of Tuebingen, Reutlingen, Germany.
Meike JakobiNMI Natural and Medical Sciences Institute at the University of Tuebingen, Reutlingen, Germany.
Benjamin RöbenDepartment of Neurodegeneration and Hertie-Institute for Clinical Brain Research, Center of Neurology, University of Tuebingen, Tuebingen, Germany.ORCID http://orcid.org/0000-0002-4905-8698
Isabel WursterDepartment of Neurodegeneration and Hertie-Institute for Clinical Brain Research, Center of Neurology, University of Tuebingen, Tuebingen, Germany.
Stefanie LercheDepartment of Neurodegeneration and Hertie-Institute for Clinical Brain Research, Center of Neurology, University of Tuebingen, Tuebingen, Germany.ORCID http://orcid.org/0000-0002-5508-004X
Claudia SchulteDepartment of Neurodegeneration and Hertie-Institute for Clinical Brain Research, Center of Neurology, University of Tuebingen, Tuebingen, Germany.
Shahrzad ZimmermannDepartment of Neurodegeneration and Hertie-Institute for Clinical Brain Research, Center of Neurology, University of Tuebingen, Tuebingen, Germany.
Christian DeuschleDepartment of Neurodegeneration and Hertie-Institute for Clinical Brain Research, Center of Neurology, University of Tuebingen, Tuebingen, Germany.
Nicole Schneiderhan-MarraNMI Natural and Medical Sciences Institute at the University of Tuebingen, Reutlingen, Germany.ORCID http://orcid.org/0000-0001-6785-181X
Thomas O JoosNMI Natural and Medical Sciences Institute at the University of Tuebingen, Reutlingen, Germany.
Thomas GasserDepartment of Neurodegeneration and Hertie-Institute for Clinical Brain Research, Center of Neurology, University of Tuebingen, Tuebingen, Germany.ORCID http://orcid.org/0000-0002-1069-1146
Kathrin BrockmannDepartment of Neurodegeneration and Hertie-Institute for Clinical Brain Research, Center of Neurology, University of Tuebingen, Tuebingen, Germany.ORCID http://orcid.org/0000-0002-7515-8596

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Parkinson's disease (PD) exhibits substantial phenotypic variability, likely influenced, at least in part, by proteins associated with pathways integral to aging processes. Plasminogen activator inhibitor-1 (SERPIN E1) is known for its association with aging processes and exacerbated α-Synuclein pathology. We examined whether SERPIN E1 levels in cerebrospinal fluid (CSF) differ among controls (CON, N = 16) and patients with PD (N = 479) or Dementia with Lewy bodies (DLB, N = 67), considering that these conditions represent a spectrum of α-Synuclein pathology. Kaplan-Meier survival analysis stratified by SERPIN E1 tertile levels was conducted to evaluate phenotype-modifying effects. Elevated levels of SERPIN E1 exhibited an association with increased age and lower MOCA scores. Heightened SERPIN E1 levels were observed in individuals diagnosed with DLB, followed by PD and CON, and in males compared to females. The quantification of SERPIN E1 in CSF could potentially serve as a surrogate marker, depicting (pathological) aging processes.

Identifiers

PMID40514404
PMCPMC12166053

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.